<DOC>
	<DOCNO>NCT02731690</DOCNO>
	<brief_summary>This open-label multi center study evaluate safety Aceneuramic Acid Extended Release ( Ace-ER ) Tablets patient GNE Myopathy.The primary objective Phase 2 study evaluate safety open-label 6 g/day Ace-ER GNEM subject severe ambulatory impairment . The study also assess efficacy ensure full spectrum patient GNEM evaluate .</brief_summary>
	<brief_title>A Study Evaluate Safety Aceneuramic Acid Extended Release ( Ace-ER ) Tablets GNE Myopathy ( GNEM ) ( Also Known Hereditary Inclusion Body Myopathy ( HIBM ) ) Patients With Severe Ambulatory Impairment</brief_title>
	<detailed_description>GNEM ( HIBM ) , rare , severely debilitate disease adult onset myopathy progressive muscle weakness cause defect biosynthetic pathway sialic acid ( SA ) . Substrate replacement potential therapeutic strategy base success replace reduce SA result reduction muscle disease relevant mouse model human disease . The primary objective Phase 2 study evaluate safety open-label 6 g/day Ace-ER GNEM subject severe ambulatory impairment . The study also assess efficacy ensure full spectrum patient GNEM evaluate .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Distal Myopathies</mesh_term>
	<criteria>Male female , age ≥ 18 year old Willing able provide write , sign informed consent nature study explain , researchrelated procedure conduct Have document diagnosis GNEM , HIBM , distal myopathy rim vacuole ( DMRV ) , Nonaka disease due previously demonstrate mutation gene encode GNE/MNK enzyme ( genotyping conduct study ) . Should meet criterion severe ambulatory impairment define : Unable rise seat position stand without help another person , assistive device ( ) , stationary object , support AND Unable walk without assistance another person OR able walk ( use assistive device ( ) permit ) , require least 2 minute walk 40 meter ( one full lap 6MWT course ) AND Use wheelchair scooter activity outside home unable leave home independently Willing able comply study procedures Participants child‐bearing potential partner childbearing potential undergone bilateral salpingo‐oophorectomy sexually active must consent use highly effective method contraception determine site investigator ( i.e . oral hormonal contraceptive , patch hormonal contraceptive , vaginal ring , intrauterine device , physical doublebarrier method , surgical hysterectomy , vasectomy , tubal ligation true abstinence ( line prefer usual lifestyle subject ) mean sex subject chooses ) , period follow signing informed consent 30 day last dose study drug Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include menopause least two year , tubal ligation least one year prior Screening , total hysterectomy bilateral salpingooophorectomy Ingestion NacetylDmannosamine ( ManNAc ) , SA , related metabolite ; intravenous immunoglobulin ( IVIG ) ; anything metabolize produce SA body within 60 day prior Screening Visit Prior participation clinical trial involve treatment AceER/placebo and/or Sialic Acid immediate release ( SAIR ) past year Has hypersensitivity SA excipients , judgment investigator , place subject increase risk adverse effect Has serum transaminase ( i.e . aspartate aminotransferase [ AST ] gammaglutamyl transpeptidase [ GGT ] ) level great 3X upper limit normal ( ULN ) age/gender , serum creatinine great 2X ULN Screening Pregnant breastfeed Screening plan become pregnant ( self partner ) time study Use investigational product investigational medical device within 30 day prior Screening , anticipate requirement investigational agent prior completion schedule study assessment Has condition severity acuity , opinion investigator , warrant immediate surgical intervention treatment may allow safe participation study Has concurrent disease , active suicidal ideation , condition , view investigator , place subject high risk poor treatment compliance complete study , would interfere study participation would affect safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GNE Myopathy</keyword>
	<keyword>Nonaka</keyword>
	<keyword>GNEM</keyword>
	<keyword>Hereditary Inclusion Body Myopathy</keyword>
	<keyword>HIBM</keyword>
	<keyword>DMRV</keyword>
	<keyword>QSM</keyword>
</DOC>